166 related articles for article (PubMed ID: 23391120)
21. LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma.
Osoegawa A; Kometani T; Nosaki K; Ondo K; Hamatake M; Hirai F; Seto T; Sugio K; Ichinose Y
Jpn J Clin Oncol; 2011 Sep; 41(9):1132-7. PubMed ID: 21816872
[TBL] [Abstract][Full Text] [Related]
22. 2007 Annual Meeting of the National Lung Cancer Partnership: a summary of meeting highlights.
Vidaver RM; Schachter BS
J Thorac Oncol; 2008 Feb; 3(2):190-3. PubMed ID: 18303443
[TBL] [Abstract][Full Text] [Related]
23. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung.
Soh J; Toyooka S; Ichihara S; Asano H; Kobayashi N; Suehisa H; Otani H; Yamamoto H; Ichimura K; Kiura K; Gazdar AF; Date H
J Thorac Oncol; 2008 Apr; 3(4):340-7. PubMed ID: 18379350
[TBL] [Abstract][Full Text] [Related]
24. Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Ferté C; Besse B; Dansin E; Parent F; Buisine MP; Copin MC; Penel N; Soria JC
Ann Oncol; 2010 Jun; 21(6):1385-1387. PubMed ID: 20501506
[No Abstract] [Full Text] [Related]
25. Bronchioloalveolar carcinoma: the "changing face of lung cancer".
Gandara DR
Clin Lung Cancer; 2006 Mar; 7(5):299. PubMed ID: 16640799
[No Abstract] [Full Text] [Related]
26. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.
Chaft JE; Rekhtman N; Ladanyi M; Riely GJ
J Thorac Oncol; 2012 Apr; 7(4):768-9. PubMed ID: 22425930
[No Abstract] [Full Text] [Related]
27. Bronchiolo-alveolar cell carcinoma of the lung.
Saraste K; Tala P; Maamies TJ
Ann Chir Gynaecol Fenn; 1968; 57(4):488-92. PubMed ID: 4307477
[No Abstract] [Full Text] [Related]
28. New discoveries in lung cancer highlighted at conference.
Printz C
Cancer; 2014 Jun; 120(11):1598-9. PubMed ID: 24844819
[No Abstract] [Full Text] [Related]
29. Cancer: A Ras and NF-kappaB pas de deux.
Chenette EJ
Nat Rev Drug Discov; 2009 Dec; 8(12):932. PubMed ID: 19967799
[No Abstract] [Full Text] [Related]
30. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
Jones S
Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
[No Abstract] [Full Text] [Related]
31. EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.
Ulivi P; Zoli W; Chiadini E; Capelli L; Candoli P; Calistri D; Silvestrini R; Puccetti M
Eur Respir J; 2012 Jul; 40(1):267-9. PubMed ID: 22753836
[No Abstract] [Full Text] [Related]
32. [Basic principles for the prevention, diagnosis and therapy of lung cancer].
Gyula O; András B; Zoltán B; Katalin B; Attila C; Janos F; Maria G; Akos H; Lászlo K; Lászlo K; Gabor K; Gyorgy L; Judit M; Tamas MF; Zsuzsa M; Pál R; Zsolt O; János S; Zoltán S; István S; Klára S; Jozsef T; Edina T;
Magy Onkol; 2012 May; 56(2):114-32. PubMed ID: 22724157
[No Abstract] [Full Text] [Related]
33. Can K-ras-mutated atypical adenomatous hyperplasia be another precursor lesion for mucinous bronchioloalveolar carcinoma?
Garfield D
Am J Clin Pathol; 2008 Aug; 130(2):315-6; author reply 316. PubMed ID: 18697292
[No Abstract] [Full Text] [Related]
34. T-Cell Transfer Therapy Targeting Mutant KRAS.
Rech AJ; Vonderheide RH
N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28207208
[No Abstract] [Full Text] [Related]
35. T-Cell Transfer Therapy Targeting Mutant KRAS.
Rosenberg SA; Tran E; Robbins PF
N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28199803
[No Abstract] [Full Text] [Related]
36. Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?
Levy BP; Drilon A; Makarian L; Patel AA; Grossbard ML
Oncology (Williston Park); 2010 Sep; 24(10):888-98, 900. PubMed ID: 21138169
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutation analysis as a diagnostic tool.
Yan B; Chin SY; Ismail TM; Salto-Tellez M
Int J Colorectal Dis; 2011 Aug; 26(8):1083-4. PubMed ID: 21128077
[No Abstract] [Full Text] [Related]
38. T-Cell Transfer Therapy Targeting Mutant KRAS.
Maoz A; Rennert G; Gruber SB
N Engl J Med; 2017 Feb; 376(7):e11. PubMed ID: 28207209
[No Abstract] [Full Text] [Related]
39. [Intravascular bronchioloalveolar tumor].
Shirakusa T; Tsutsui M; Araki Y; Yoshida M; Hayashi T; Ikeda A; Kusano T; Iwasaki H; Eimoto T
Kyobu Geka; 1988 Jul; 41(8):636-40. PubMed ID: 2852271
[No Abstract] [Full Text] [Related]
40. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Lee CN; Chen HY; Liu HE
J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
